Figure 3
Figure 3. Inhibition of CDK9 rescues HSCs in pausing-deficient embryos. (Top) A schematic diagram for the predicted effect of CDK9 inhibition on HSC formation in pausing-deficient embryos in panels A-G. (A-C) WISH for runx1/c-myb at 36 hpf in control, spt5m806, and nelf-b morpholino (MO) injected embryos treated with DMSO (A), flavopiridol (B), or CDK9 inhibitor II (CDK9-i2). (D-F) WISH for runx1/c-myb at 36 hpf in control and spt5m806 embryos injected with control MO (D), 1.2 ng cdk9 MO (E), or 4 ng cdk9 MO (F). (G) WISH for runx1/c-myb at 36 hpf in control and spt5m806 embryos treated with high-dose (500 μM) CDK9-i2. DMSO, dimethyl sulfoxide.

Inhibition of CDK9 rescues HSCs in pausing-deficient embryos. (Top) A schematic diagram for the predicted effect of CDK9 inhibition on HSC formation in pausing-deficient embryos in panels A-G. (A-C) WISH for runx1/c-myb at 36 hpf in control, spt5m806, and nelf-b morpholino (MO) injected embryos treated with DMSO (A), flavopiridol (B), or CDK9 inhibitor II (CDK9-i2). (D-F) WISH for runx1/c-myb at 36 hpf in control and spt5m806 embryos injected with control MO (D), 1.2 ng cdk9 MO (E), or 4 ng cdk9 MO (F). (G) WISH for runx1/c-myb at 36 hpf in control and spt5m806 embryos treated with high-dose (500 μM) CDK9-i2. DMSO, dimethyl sulfoxide.

Close Modal

or Create an Account

Close Modal
Close Modal